论文部分内容阅读
[目的]观察依达拉奉治疗急性脑出血的临床疗效。[方法]将60例脑出血患者随机分为治疗组(30例)和对照组(30例)。治疗组在急性脑出血常规治疗的基础上,给予依达拉奉注射液30mg,加入0.9%氯化钠注射液250ml中静滴,2次/d,疗程14d。分别于治疗前后进行神经功能缺损评分,并进行统计学分析。[结果]治疗14d后治疗组神经功能缺损评分明显低于对照组(P﹤0.05);治疗组的总有效率显著高于对照组(P﹤0.05)。[结论]依达拉奉能促进急性脑出血患者的神经功能康复,是一种治疗急性脑出血安全有效的药物。
[Objective] To observe the clinical efficacy of edaravone in the treatment of acute cerebral hemorrhage. [Methods] Sixty ICH patients were randomly divided into treatment group (30 cases) and control group (30 cases). On the basis of conventional treatment of acute intracerebral hemorrhage, the treatment group was treated with edaravone 30mg intravenously, 250ml of 0.9% sodium chloride injection was intravenously dripped twice daily for 14 days. Neurological deficits were assessed before and after treatment, and statistical analysis was performed. [Results] The score of neurological deficit in the treatment group after 14 days of treatment was significantly lower than that of the control group (P <0.05). The total effective rate of the treatment group was significantly higher than that of the control group (P <0.05). [Conclusion] Edaravone can promote neurological rehabilitation in patients with acute cerebral hemorrhage and is a safe and effective drug in the treatment of acute cerebral hemorrhage.